Functional characterization of the 19q12 amplicon in grade III breast cancers

Breast Cancer Research

Volumn 14, Issue 2, 2012, Pages

  Natrajan, Rachael ^a   Mackay, Alan ^a   Wilkerson, Paul M ^a   Lambros, Maryou B ^a   Wetterskog, Daniel ^a   Arnedos, Monica ^a   Shiu, Kai Keen ^a   Geyer, Felipe C ^a   Langerød, Anita ^b   Kreike, Bas ^c   Reyal, Fabien ^d   Horlings, Hugo M ^e   van de Vijver, Marc J ^e   Palacios, Jose ^f   Weigelt, Britta ^g   Reis Filho, Jorge S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c Institute for Radiation Oncology Arnhem   (Netherlands)

^d INSTITUT CURIE   (France)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN E1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; PLECKSTRIN HOMOLOGY DOMAIN CONTAINING FAMILY F WITH FYVE DOMAIN MEMBER 1 PROTEIN; PROCESSING OF PRECURSOR 4 RIBONUCLEASE P MRP SUBUNIT PROTEIN; PROTEIN; SMALL INTERFERING RNA; TEASHIRT ZINC FINGER HOMEOBOX 3 PROTEIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CCNE1 PROTEIN, HUMAN; CDK2 PROTEIN, HUMAN; CYCLIN E; HOMEODOMAIN PROTEIN; ONCOPROTEIN; PLEKHF1 PROTEIN, HUMAN; POP4 PROTEIN, HUMAN; RIBONUCLEASE; RIBONUCLEOPROTEIN; TSHZ3 PROTEIN, HUMAN;

AMPLICON; ARTICLE; BREAST CANCER; C19ORF12 GENE; CANCER CELL; CANCER GRADING; CANCER TISSUE; CELL SURVIVAL; CELL VIABILITY; CHROMOSOME 19Q; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; CYCLIN E1 GENE; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE IN SITU HYBRIDIZATION; FROZEN SECTION; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCUS; GENE MAPPING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PHENOTYPE; PLECKSTRIN HOMOLOGY DOMAIN CONTAINING FAMILY F WITH FYVE DOMAIN MEMBER 1 GENE; PROCESSING OF PRECURSOR 4 RIBONUCLEASE P MRP SUBUNIT GENE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RPB5 MEDIATING PROTEIN GENE; TEASHIRT ZINC FINGER HOMEOBOX 3 GENE; UBIQUINOL CYTOCHROME C REDUCTASE RIESKE IRON SULFUR POLYPEPTIDE 1 GENE; WESTERN BLOTTING; ZINC FINGER PROTEIN 536 GENE; BREAST TUMOR; CHROMOSOME 19; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 19; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; NEOPLASM GRADING; ONCOGENE PROTEINS; RECEPTORS, ESTROGEN; RIBONUCLEASES; RIBONUCLEOPROTEINS; RNA INTERFERENCE;

EID: 84858391640     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3154     Document Type: Article

References (70)

1. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011, 378:1812-1823. 10.1016/S0140-6736(11)61539-0, 22098854.
2. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009, 360:790-800. 10.1056/NEJMra0801289, 19228622.
3. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010, 220:263-280.
4. Colombo PE, Milanezi F, Weigelt B, Reis-Filho JS. Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res 2011, 13:212. 10.1186/bcr2890, 3218943, 21787441.
5. Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang CY, Santarpia L, Matsuoka J, Hortobagyi GN, Symmans WF, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Andre F, Simon R, Pusztai L. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 2011, 103:264-272. 10.1093/jnci/djq524, 21191116.
6. Weigelt B, Pusztai L, Ashworth A, Reis-Filho JS. Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol 2011, 9:58-64. 10.1038/nrclinonc.2011.125, 21878891.
7. Jonsson G, Staaf J, Vallon-Christersson J, Ringner M, Holm K, Hegardt C, Gunnarsson H, Fagerholm R, Strand C, Agnarsson BA, Kilpivaara O, Luts L, Heikkila P, Aittomaki K, Blomqvist C, Loman N, Malmstrom P, Olsson H, Johannsson OT, Arason A, Nevanlinna H, Barkardottir RB, Borg A. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res 2010, 12:R42. 10.1186/bcr2596, 2917037, 20576095.
8. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer C, Teague JW, Lau KW, Burton J, Quail MA, Swerdlow H, Churcher C, Natrajan R, Sieuwerts AM, Martens JW, Silver DP, Langerod A, Russnes HE, Foekens JA, Reis-Filho JS, van 't Veer L, Richardson AL, Borresen-Dale AL, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009, 462:1005-1010. 10.1038/nature08645, 20033038.
9. Natrajan R, Lambros MB, Rodriguez-Pinilla SM, Moreno-Bueno G, Tan DS, Marchio C, Vatcheva R, Rayter S, Mahler-Araujo B, Fulford LG, Hungermann D, Mackay A, Grigoriadis A, Fenwick K, Tamber N, Hardisson D, Tutt A, Palacios J, Lord CJ, Buerger H, Ashworth A, Reis-Filho JS. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 2009, 15:2711-2722. 10.1158/1078-0432.CCR-08-1878, 19318498.
10. Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, Grigoriadis A, Sarrio D, Savage K, Dexter T, Iravani M, Fenwick K, Weber B, Hardisson D, Schmitt FC, Palacios J, Lakhani SR, Ashworth A. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006, 12:6652-6662. 10.1158/1078-0432.CCR-06-1164, 17121884.
11. Bernard-Pierrot I, Gruel N, Stransky N, Vincent-Salomon A, Reyal F, Raynal V, Vallot C, Pierron G, Radvanyi F, Delattre O. Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. Cancer Res 2008, 68:7165-7175. 10.1158/0008-5472.CAN-08-1360, 18757432.
12. Bocanegra M, Bergamaschi A, Kim YH, Miller MA, Rajput AB, Kao J, Langerod A, Han W, Noh DY, Jeffrey SS, Huntsman DG, Borresen-Dale AL, Pollack JR. Focal amplification and oncogene dependency of GAB2 in breast cancer. Oncogene 2010, 29:774-779. 10.1038/onc.2009.364, 19881546.
13. Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C, Richon C, Yan K, Wang B, Vassal G, Delaloge S, Hortobagyi GN, Symmans WF, Lazar V, Pusztai L. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009, 15:441-451. 10.1158/1078-0432.CCR-08-1791, 19147748.
14. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10:529-541. 10.1016/j.ccr.2006.10.009, 17157792.
15. Chin SF, Teschendorff AE, Marioni JC, Wang Y, Barbosa-Morais NL, Thorne NP, Costa JL, Pinder SE, van de Wiel MA, Green AR, Ellis IO, Porter PL, Tavare S, Brenton JD, Ylstra B, Caldas C. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol 2007, 8:R215. 10.1186/gb-2007-8-10-r215, 2246289, 17925008.
16. Mackay A, Tamber N, Fenwick K, Iravani M, Grigoriadis A, Dexter T, Lord CJ, Reis-Filho JS, Ashworth A. A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. Breast Cancer Res Treat 2009, 118:481-498. 10.1007/s10549-008-0296-7, 19169812.
17. Holland DG, Burleigh A, Git A, Goldgraben MA, Perez-Mancera PA, Chin SF, Hurtado A, Bruna A, Ali HR, Greenwood W, Dunning MJ, Samarajiwa S, Menon S, Rueda OM, Lynch AG, McKinney S, Ellis IO, Eaves CJ, Carroll JS, Curtis C, Aparicio S, Caldas C. ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med 2011, 3:167-180. 10.1002/emmm.201100122, 21337521.
18. Sircoulomb F, Nicolas N, Ferrari A, Finetti P, Bekhouche I, Rousselet E, Lonigro A, Adelaide J, Baudelet E, Esteyries S, Wicinski J, Audebert S, Charafe-Jauffret E, Jacquemier J, Lopez M, Borg JP, Sotiriou C, Popovici C, Bertucci F, Birnbaum D, Chaffanet M, Ginestier C. ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med 2011, 3:153-166. 10.1002/emmm.201100121, 21328542.
19. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010, 70:2085-2094. 10.1158/0008-5472.CAN-09-3746, 2832818, 20179196.
20. Arriola E, Marchio C, Tan DS, Drury SC, Lambros MB, Natrajan R, Rodriguez-Pinilla SM, Mackay A, Tamber N, Fenwick K, Jones C, Dowsett M, Ashworth A, Reis-Filho JS. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 2008, 88:491-503. 10.1038/labinvest.2008.19, 18332872.
21. Orsetti B, Nugoli M, Cervera N, Lasorsa L, Chuchana P, Ursule L, Nguyen C, Redon R, du Manoir S, Rodriguez C, Theillet C. Genomic and expression profiling of chromosome 17 in breast cancer reveals complex patterns of alterations and novel candidate genes. Cancer Res 2004, 64:6453-6460. 10.1158/0008-5472.CAN-04-0756, 15374954.
22. Staaf J, Jonsson G, Ringner M, Vallon-Christersson J, Grabau D, Arason A, Gunnarsson H, Agnarsson BA, Malmstrom PO, Johannsson OT, Loman N, Barkardottir RB, Borg A. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res 2010, 12:R25. 10.1186/bcr2568, 2917012, 20459607.
23. Kao J, Pollack JR. RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Genes Chromosomes Cancer 2006, 45:761-769. 10.1002/gcc.20339, 16708353.
24. Shiu KK, Natrajan R, Geyer FC, Ashworth A, Reis-Filho JS. DNA amplifications in breast cancer: genotypic-phenotypic correlations. Future Oncol 2010, 6:967-984. 10.2217/fon.10.56, 20528234.
25. Streicher KL, Yang ZQ, Draghici S, Ethier SP. Transforming function of the LSM1 oncogene in human breast cancers with the 8p11-12 amplicon. Oncogene 2007, 26:2104-2114. 10.1038/sj.onc.1210002, 2435249, 17001308.
26. Adelaide J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F, Charafe-Jauffret E, Cervera N, Desplans J, Parzy D, Schoenmakers E, Viens P, Jacquemier J, Birnbaum D, Bertucci F, Chaffanet M. Integrated profiling of basal and luminal breast cancers. Cancer Res 2007, 67:11565-11575. 10.1158/0008-5472.CAN-07-2536, 18089785.
27. Moelans CB, de Weger RA, Monsuur HN, Vijzelaar R, van Diest PJ. Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol 2010, 23:1029-1039. 10.1038/modpathol.2010.84, 20473280.
28. Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, de Weerd V, Portengen H, Klijn JG, Foekens JA. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res 2006, 12:3319-3328. 10.1158/1078-0432.CCR-06-0225, 16740753.
29. Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS, Jones C, Lord CJ, Vatcheva R, Rodriguez-Pinilla SM, Palacios J, Ashworth A, Reis-Filho JS. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 2010, 121:575-589. 10.1007/s10549-009-0501-3, 19688261.
30. Hungermann D, Schmidt H, Natrajan R, Tidow N, Poos K, Reis-Filho JS, Brandt B, Buerger H, Korsching E. Influence of whole arm loss of chromosome 16q on gene expression patterns in oestrogen receptor-positive, invasive breast cancer. J Pathol 2011, 224:517-528. 10.1002/path.2938, 21706489.
31. Kreike B, Hart G, Bartelink H, van de Vijver MJ. Analysis of breast cancer related gene expression using natural splines and the Cox proportional hazard model to identify prognostic associations. Breast Cancer Res Treat 2010, 122:711-720. 10.1007/s10549-009-0588-6, 19859804.
32. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002, 41:154-161.
33. Lacroix-Triki M, Suarez PH, MacKay A, Lambros MB, Natrajan R, Savage K, Geyer FC, Weigelt B, Ashworth A, Reis-Filho JS. Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol 2010, 222:282-298. 10.1002/path.2763, 20815046.
34. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, Goldstein DR, Piccart M, Delorenzi M. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008, 10:R65. 10.1186/bcr2124, 2575538, 18662380.
35. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008, 14:5158-5165. 10.1158/1078-0432.CCR-07-4756, 18698033.
36. Weigelt B, Mackay A, A'Hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010, 11:339-349. 10.1016/S1470-2045(10)70008-5, 20181526.
37. Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, Bibeau F, Macgrogan G, Lerebours F, Finetti P, Longy M, Bertheau P, Bertrand F, Bonnet F, Martin AL, Feugeas JP, Bieche I, Lehmann-Che J, Lidereau R, Birnbaum D, Bertucci F, de Thé H, Theillet C. A refined molecular taxonomy of breast cancer. Oncogene 2012, 31:1196-1206. 10.1038/onc.2011.301, 3307061, 21785460.
38. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527. 10.1016/j.ccr.2006.10.008, 2730521, 17157791.
39. Geyer FC, Weigelt B, Natrajan R, Lambros MB, de Biase D, Vatcheva R, Savage K, Mackay A, Ashworth A, Reis-Filho JS. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol 2010, 220:562-573. 10.1002/path.2675, 20099298.
40. Coe BP, Ylstra B, Carvalho B, Meijer GA, Macaulay C, Lam WL. Resolving the resolution of array CGH. Genomics 2007, 89:647-653. 10.1016/j.ygeno.2006.12.012, 17276656.
41. Gunnarsson R, Staaf J, Jansson M, Ottesen AM, Goransson H, Liljedahl U, Ralfkiaer U, Mansouri M, Buhl AM, Smedby KE, Hjalgrim H, Syvanen AC, Borg A, Isaksson A, Jurlander J, Juliusson G, Rosenquist R. Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia--a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 2008, 47:697-711. 10.1002/gcc.20575, 18484635.
42. Tan DS, Lambros MB, Natrajan R, Reis-Filho JS. Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research. Lab Invest 2007, 87:737-754. 10.1038/labinvest.3700593, 17558419.
43. Ensembl Genome Browser. , http://www.ensembl.org
44. Wilkerson PM, Dedes KJ, Wetterskog D, Mackay A, Lambros MB, Mansour M, Frankum J, Lord CJ, Natrajan R, Ashworth A, Reis-Filho JS. Functional characterization of EMSY gene amplification in human cancers. J Pathol 2011, 225:29-42. 10.1002/path.2944, 21735447.
45. Marchio C, Lambros MB, Gugliotta P, Di Cantogno LV, Botta C, Pasini B, Tan DS, Mackay A, Fenwick K, Tamber N, Bussolati G, Ashworth A, Reis-Filho JS, Sapino A. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 2009, 219:16-24. 10.1002/path.2574, 19670217.
46. Duprez R, Wilkerson PM, Lacroix-Triki M, Lambros MB, Mackay A, Hern RA, Gauthier A, Pawar V, Colombo PE, Daley F, Natrajan R, Ward E, Macgrogan G, Arbion F, Michenet P, Weigelt B, Vincent-Salomon A, Reis-Filho JS. Immunophenotypic and genomic characterization of papillary carcinomas of the breast. J Pathol 2012, 226:427-441. 10.1002/path.3032, 22025283.
47. Natrajan.19q12.amplicon. , http://www.rock.icr.ac.uk/collaborations/Natrajan/19q12.amplicon/
48. Lambros MB, Simpson PT, Jones C, Natrajan R, Westbury C, Steele D, Savage K, Mackay A, Schmitt FC, Ashworth A, Reis-Filho JS. Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest 2006, 86:398-408. 10.1038/labinvest.3700390, 16446704.
49. Zhou W, Muggerud AA, Vu P, Due EU, Sørlie T, Børresen-Dale AL, Warnberg F, Langerod A. Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution. Mol Oncol 2009, 3:214-219. 10.1016/j.molonc.2009.03.001, 19403344.
50. Armstrong AB, Wang M, Eble JN, MacLennan GT, Montironi R, Tan PH, Lopez-Beltran A, Zhang S, Baldridge LA, Spartz H, Cheng L. TP53 mutational analysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder. Mod Pathol 2009, 22:113-118. 10.1038/modpathol.2008.176, 18997737.
51. ArrayExpress. , http://www.ebi.ac.uk/microarray-as/ae/
52. Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, Rayter S, Tutt AN, Ashworth A. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 2008, 27:1368-1377. 10.1038/emboj.2008.61, 2374839, 18388863.
53. ImageJ. , http://rsbweb.nih.gov/ij/index.html
54. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, Liu J, Smith-McCune K, Lu KH, Fishman D, Gray JW, Mills GB. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 2004, 10:1251-1256. 10.1038/nm1125, 15502842.
55. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009, 9:153-166. 10.1038/nrc2602, 19238148.
56. Anderson M, Andrews DM, Barker AJ, Brassington CA, Breed J, Byth KF, Culshaw JD, Finlay MR, Fisher E, McMiken HH, Green CP, Heaton DW, Nash IA, Newcombe NJ, Oakes SE, Pauptit RA, Roberts A, Stanway JJ, Thomas AP, Tucker JA, Walker M, Weir HM. Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett 2008, 18:5487-5492. 10.1016/j.bmcl.2008.09.024, 18815031.
57. Byth KF, Thomas A, Hughes G, Forder C, McGregor A, Geh C, Oakes S, Green C, Walker M, Newcombe N, Green S, Growcott J, Barker A, Wilkinson RW. AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Mol Cancer Ther 2009, 8:1856-1866. 10.1158/1535-7163.MCT-08-0836, 19509270.
58. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, Tutt AN. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007, 26:2126-2132. 10.1038/sj.onc.1210014, 17016441.
59. Leung SY, Ho C, Tu IP, Li R, So S, Chu KM, Yuen ST, Chen X. Comprehensive analysis of 19q12 amplicon in human gastric cancers. Mod Pathol 2006, 19:854-863.
60. Courjal F, Cuny M, Simony-Lafontaine J, Louason G, Speiser P, Zeillinger R, Rodriguez C, Theillet C. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res 1997, 57:4360-4367.
61. Chen W, Li N, Chen T, Han Y, Li C, Wang Y, He W, Zhang L, Wan T, Cao X. The lysosome-associated apoptosis-inducing protein containing the pleckstrin homology (PH) and FYVE domains (LAPF), representative of a novel family of PH and FYVE domain-containing proteins, induces caspase-independent apoptosis via the lysosomal-mitochondrial pathway. J Biol Chem 2005, 280:40985-40995. 10.1074/jbc.M502190200, 16188880.
62. Li N, Zheng Y, Chen W, Wang C, Liu X, He W, Xu H, Cao X. Adaptor protein LAPF recruits phosphorylated p53 to lysosomes and triggers lysosomal destabilization in apoptosis. Cancer Res 2007, 67:11176-11185. 10.1158/0008-5472.CAN-07-2333, 18056442.
63. Caubit X, Lye CM, Martin E, Core N, Long DA, Vola C, Jenkins D, Garratt AN, Skaer H, Woolf AS, Fasano L. Teashirt 3 is necessary for ureteral smooth muscle differentiation downstream of SHH and BMP4. Development 2008, 135:3301-3310. 10.1242/dev.022442, 18776146.
64. Faralli H, Martin E, Core N, Liu QC, Filippi P, Dilworth FJ, Caubit X, Fasano L. Teashirt-3, a novel regulator of muscle differentiation, associates with BRG-1 associated factor 57 (BAF57) to inhibit myogenin gene expression. J Biol Chem 2011,
65. Yamamoto M, Cid E, Bru S, Yamamoto F. Rare and frequent promoter methylation, respectively, of TSHZ2 and 3 genes that are both downregulated in expression in breast and prostate cancers. PLoS One 2011, 6:e17149. 10.1371/journal.pone.0017149, 3056709, 21423795.
66. Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, Miyazaki K. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 2010, 116:2621-2634.
67. Etemadmoghadam D, George J, Cowin PA, Cullinane C, Kansara M, Gorringe KL, Smyth GK, Bowtell DD. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS One 2010, 5:e15498. 10.1371/journal.pone.0015498, 2980490, 21103391.
68. Akli S, Van Pelt CS, Bui T, Meijer L, Keyomarsi K. Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of Cyclin E. Cancer Res 2011, 71:3377-3386. 10.1158/0008-5472.CAN-10-4086, 21385896.
69. The TP53 website. , http://p53.free.fr/Database/Cancer_cell_lines/Breast_cancer.html
70. Catalogue Of Somatic Mutations In Cancer. , http://www.sanger.ac.uk/genetics/CGP/cosmic/